Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNYSE:EBS
CUSIP29089Q10
Phone240-631-3200
Debt
Debt-to-Equity Ratio0.02
Current Ratio5.49
Quick Ratio3.70
Price-To-Earnings
Trailing P/E Ratio33.33
Forward P/E Ratio22.09
P/E Growth1.11
Sales & Book Value
Annual Sales$560.87 million
Price / Sales4.61
Cash Flow$2.7754 per share
Price / Cash18.70
Book Value$18.47 per share
Price / Book2.81
Profitability
EPS (Most Recent Fiscal Year)$1.90
Net Income$82.59 million
Net Margins11.96%
Return on Equity10.39%
Return on Assets7.74%
Miscellaneous
Employees1,256
Outstanding Shares49,820,000
Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions
What is Emergent Biosolutions' stock symbol?
Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."
How will Emergent Biosolutions' stock buyback program work?
Emergent Biosolutions announced that its board has authorized a stock buyback plan on Friday, March 23rd 2018, which authorizes the company to buyback $50,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company's board believes its stock is undervalued.
How were Emergent Biosolutions' earnings last quarter?
Emergent Biosolutions Inc (NYSE:EBS) issued its quarterly earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.03) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.22 by $0.25. The biopharmaceutical company earned $117.80 million during the quarter, compared to analysts' expectations of $140.42 million. Emergent Biosolutions had a net margin of 11.96% and a return on equity of 10.39%. The business's revenue was up .8% on a year-over-year basis. During the same period in the prior year, the business earned $0.23 EPS. View Emergent Biosolutions' Earnings History.
When is Emergent Biosolutions' next earnings date?
What price target have analysts set for EBS?
6 Wall Street analysts have issued 12 month price objectives for Emergent Biosolutions' stock. Their predictions range from $53.00 to $62.00. On average, they expect Emergent Biosolutions' share price to reach $58.00 in the next year. View Analyst Ratings for Emergent Biosolutions.
Who are some of Emergent Biosolutions' key competitors?
Some companies that are related to Emergent Biosolutions include Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), BeiGene (BGNE), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Loxo Oncology (LOXO), FibroGen (FGEN), Ionis Pharmaceuticals (IONS) and United Therapeutics (UTHR).
Who are Emergent Biosolutions' key executives?
Emergent Biosolutions' management team includes the folowing people:
- Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 60)
- Mr. Daniel J. Abdun-Nabi, CEO & Director (Age 63)
- Mr. Robert G. Kramer Sr., Pres & COO (Age 61)
- Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 45)
- Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 47)
Has Emergent Biosolutions been receiving favorable news coverage?
News stories about EBS stock have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Emergent Biosolutions earned a news impact score of 0.07 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.91 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Emergent Biosolutions' major shareholders?
Emergent Biosolutions' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.97%), Dimensional Fund Advisors LP (4.43%), Summit Trail Advisors LLC (2.77%), Royal Bank of Canada (2.35%), Millennium Management LLC (1.84%) and Russell Investments Group Ltd. (1.14%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.
Which major investors are selling Emergent Biosolutions stock?
EBS stock was sold by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , LSV Asset Management, Federated Investors Inc. PA, Amundi Pioneer Asset Management Inc., FIL Ltd, Royal Bank of Canada, Guggenheim Capital LLC and Fisher Asset Management LLC. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions.
Which major investors are buying Emergent Biosolutions stock?
EBS stock was acquired by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Matarin Capital Management LLC, Prudential Financial Inc., Millennium Management LLC, Russell Investments Group Ltd., Monarch Partners Asset Management LLC, UBS Group AG and Allianz Asset Management GmbH. View Insider Buying and Selling for Emergent Biosolutions.
How do I buy shares of Emergent Biosolutions?
Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Emergent Biosolutions' stock price today?
One share of EBS stock can currently be purchased for approximately $51.90.
How big of a company is Emergent Biosolutions?
Emergent Biosolutions has a market capitalization of $2.61 billion and generates $560.87 million in revenue each year. The biopharmaceutical company earns $82.59 million in net income (profit) each year or $1.90 on an earnings per share basis. Emergent Biosolutions employs 1,256 workers across the globe.
How can I contact Emergent Biosolutions?
Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]
MarketBeat Community Rating for Emergent Biosolutions (EBS)
MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
